tetano
Editor, Senior Moderator
J Allergy Clin Immunol Glob
. 2022 Aug;1(3):172-174.
doi: 10.1016/j.jacig.2022.03.003. Epub 2022 Apr 14.
Second-dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series
Aled Iaboni[SUP] 1 2 [/SUP], Nina Jindal[SUP] 3 [/SUP], Stephen D Betschel[SUP] 2 [/SUP], Christine Song[SUP] 3 [/SUP]
Affiliations
Abstract
Background: The rates of suspected allergic reactions to the first dose of the coronavirus disease 2019 (COVID-19) mRNA vaccines have been reported to be as high as 2%, with an anaphylaxis incidence up to 2.5 per 10,000 individuals. Anaphylaxis in response to the first dose may be considered a contraindication to administration of the second dose, even though the second dose is necessary for optimal protection against severe disease. Many individuals with anaphylactic reactions to the first dose still want to receive a second dose. However, there are few published data to support the safety of administration of a second dose in this population.
Objective: The primary objective of this study was to determine the percentage of patients tolerating a second COVID-19 mRNA vaccine dose after an immediate reaction to the first dose.
Methods: This was a retrospective chart review of 47 patients at a Canadian hospital who had immediate, suspected allergic reactions following their first COVID-19 mRNA vaccine dose and received a second dose within our allergy clinic.
Results: Of 47 patients, 46 tolerated the second dose; 43% of patients developed mild, transient symptoms. There were no patients who developed anaphylaxis or needed epinephrine after the second dose.
Conclusion: Our case series adds to current evidence that administration of a second COVID-19 mRNA vaccine dose has a good safety profile in patients with a history of immediate reactions after the first dose, including those with a history of anaphylaxis in response to the first dose.
Keywords: COVID-19; COVID-19, Coronavirus disease 2019; Coronavirus disease 2019; Moderna; PEG, Polyethylene glycol; Pfizer; allergy; anaphylaxis; mRNA; vaccine.
. 2022 Aug;1(3):172-174.
doi: 10.1016/j.jacig.2022.03.003. Epub 2022 Apr 14.
Second-dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series
Aled Iaboni[SUP] 1 2 [/SUP], Nina Jindal[SUP] 3 [/SUP], Stephen D Betschel[SUP] 2 [/SUP], Christine Song[SUP] 3 [/SUP]
Affiliations
- PMID: 36203478
- PMCID: PMC9010013
- DOI: 10.1016/j.jacig.2022.03.003
Abstract
Background: The rates of suspected allergic reactions to the first dose of the coronavirus disease 2019 (COVID-19) mRNA vaccines have been reported to be as high as 2%, with an anaphylaxis incidence up to 2.5 per 10,000 individuals. Anaphylaxis in response to the first dose may be considered a contraindication to administration of the second dose, even though the second dose is necessary for optimal protection against severe disease. Many individuals with anaphylactic reactions to the first dose still want to receive a second dose. However, there are few published data to support the safety of administration of a second dose in this population.
Objective: The primary objective of this study was to determine the percentage of patients tolerating a second COVID-19 mRNA vaccine dose after an immediate reaction to the first dose.
Methods: This was a retrospective chart review of 47 patients at a Canadian hospital who had immediate, suspected allergic reactions following their first COVID-19 mRNA vaccine dose and received a second dose within our allergy clinic.
Results: Of 47 patients, 46 tolerated the second dose; 43% of patients developed mild, transient symptoms. There were no patients who developed anaphylaxis or needed epinephrine after the second dose.
Conclusion: Our case series adds to current evidence that administration of a second COVID-19 mRNA vaccine dose has a good safety profile in patients with a history of immediate reactions after the first dose, including those with a history of anaphylaxis in response to the first dose.
Keywords: COVID-19; COVID-19, Coronavirus disease 2019; Coronavirus disease 2019; Moderna; PEG, Polyethylene glycol; Pfizer; allergy; anaphylaxis; mRNA; vaccine.